Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Multidisciplinary Center for Inflammatory Bowel Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio.
Clin Gastroenterol Hepatol. 2020 May;18(6):1356-1366. doi: 10.1016/j.cgh.2019.09.040. Epub 2019 Oct 4.
Although the number of available therapies for the treatment of ulcerative colitis and Crohn's disease (CD) continues to expand, a significant portion of patients with inflammatory bowel disease will require surgical intervention. Surgery remains an integral part of the treatment algorithm for patients with ulcerative colitis and CD, and thus multidisciplinary approaches to the perioperative and postoperative management of patients with inflammatory bowel disease are critical to improving outcomes during these periods. New mechanisms of biologic therapies are emerging and new treatment strategies focused on earlier and potentially more aggressive use of immunosuppressive therapies are advocated in the current treatment era. In this review, we outline multidisciplinary strategies for the preoperative management of immunosuppressive therapies, including a discussion of the most recent evidence regarding the safety of biologic therapy in the preoperative period. We also discuss the postoperative medical management of patients undergoing intestinal resection for CD, with a particular focus on risk stratification and appropriate therapy selection in the immediate postoperative setting. Finally, we review potential postoperative complications after restorative proctocolectomy with ileal pouch-anal anastomosis and their management.
虽然溃疡性结肠炎和克罗恩病(CD)的治疗方法不断增加,但仍有相当一部分炎症性肠病患者需要手术干预。手术仍然是溃疡性结肠炎和 CD 患者治疗方案的重要组成部分,因此,炎症性肠病患者围手术期和术后的多学科管理方法对于改善这些时期的治疗效果至关重要。新的生物治疗机制正在出现,在当前的治疗时代,提倡针对更早和潜在更积极使用免疫抑制治疗的新治疗策略。在这篇综述中,我们概述了围手术期免疫抑制治疗的多学科策略,包括讨论生物治疗在术前期间的安全性的最新证据。我们还讨论了接受 CD 肠切除术患者的术后医疗管理,特别关注术后即刻的风险分层和适当的治疗选择。最后,我们回顾了回肠贮袋肛管吻合术(restorative proctocolectomy with ileal pouch-anal anastomosis)后的潜在术后并发症及其管理。